RxDoctor Payments Data

Sudeep Aryal, MD

Cardiovascular Disease · Salisbury, NCNPI 1962780197

Payments from drug & device makers

$15,668in general payments, 2019–2025

Across 130 payments — averaging $120.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Medtronic$4K
  • Boston Scientific$3K
  • Edwards Lifesciences$2K
  • Medical Device Business Services, Inc.$504
  • E.r. Squibb & Sons, L.L.C.$163
  • plus $380 from 11 others

What the payments were for

  • Travel & lodging$9,57961%
  • Food & beverage$5,47535%
  • Education$6144%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,668 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,360
Medicare patients
197
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$275,124
VyndamaxTafamidis12$245,117
JardianceEmpagliflozin127$163,247
Repatha SureclickEvolocumab83$73,135
EntrestoSacubitril/Valsartan39$64,037
XareltoRivaroxaban43$48,250
BrilintaTicagrelor16$17,283
FarxigaDapagliflozin Propanediol16$11,211
Atorvastatin Calcium358$7,986
Rosuvastatin Calcium150$4,157
Metoprolol Succinate223$4,112
Isosorbide Dinitrate14$2,830
Spironolactone227$2,250
Losartan Potassium147$2,207
Ezetimibe79$2,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$18$520,241227 claims
NovartisEntresto$44$64,03739 claims
Johnson & JohnsonXarelto$18$48,25043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →